A week after ESPN’s Buster Olney decided that Melky Cabrera’s excellent-so-far 2014 season justifies people assuming he’s back on PEDs, ESPN’s Dan Szymborski dives into the numbers and shows that such a decision is not based on any evidence at all:
Despite the rhetoric surrounding PEDs, players caught for steroid/testosterone use do not show a pattern of overperforming their projections in the years leading up to the drug suspension or a pattern of underperforming their projections in the years after a drug suspension.
All of this is based on Szymborski’s ZiPS projection system, which shows that Cabrera is doing about what you’d expect him to do this year. And that, as a group, guys busted for PEDs don’t really deviate too much from their expected performance one way or another before, during or after they are caught for PEDs.
Obviously there are a lot of caveats in play here. Small sample sizes, imperfect data about when guys start and stop taking PEDs and, of course, the flaws any projection system, even one as generally reliable as ZiPS, brings to the table.
But if you’re making a case for something — and Olney and others who are questioning the legitimacy of Melky’s performance this season are clearly making a case for something — it’s incumbent upon you to present some evidence. Szymborski’s analysis doesn’t necessarily prove anything about the efficacy or lack thereof of PEDs. But it has far more evidence on its side than anything people are hurling at Cabrera lately.
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.